1xbet 우회

• In Japan, E Kep1xbet 우회a^® is marketed for partial-onset seizures (including secondary generalized seizures) in patients with ep1xbet 우회epsy and has been used in over 100,000 patients. It recently obtained an additional indication for adjunctive treatment of generalized tonic-clonic seizures.
• Seizures associated with ep1xbet 우회epsy are classified into two types: partial-onset seizures and generalized seizures. Generalized tonic-clonic seizures, which account for 60% of generalized seizures, feature a sudden loss of consciousness associated with generalized rigidity and violent convulsions.
• The Japan Epilepsy Society and the Japanese Society of Child Neurology petitioned the MHLW's Council on Unap1xbet 우회oved Drugs and Indications with Unmet Medical Needs, calling for the development and ap1xbet 우회oval of E Kep1xbet 우회a^® for adjunctive therapy for generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy. Its ap1xbet 우회oval is expected to contribute to the treatment of patients with these seizures.

Otsuka Pharmaceutical Co., Ltd. and UCB Japan Co., Ltd. today announced that E Kep1xbet 우회a^® was ap1xbet 우회oved in Japan for an additional indication as adjunctive therapy with other anti-epileptic drugs for generalized tonic-clonic seizures in adult patients and pediatric patients aged four years and over with epilepsy showing inadequate responses to other anti-epileptic drugs. Otsuka Pharmaceutical and UCB Japan are engaged in the co-development and co-commercialization of E Kep1xbet 우회a^® in Japan. The formulations ap1xbet 우회oved for this indication include E Kep1xbet 우회a^® Tablets 250 mg and 500 mg, E Kep1xbet 우회a^® Dry Syrup 50%, and E Kep1xbet 우회a^® for IV Infusion 500 mg.